Pacira BioSciences (NASDAQ:PCRX) Trading 4.3% Higher – What’s Next?

Pacira BioSciences, Inc. (NASDAQ:PCRX) traded up 4.3% during mid-day trading on Thursday . The stock traded as high as $23.01 and last traded at $23.00. 91,507 shares traded hands during trading, a decline of 90% from the average session volume of 891,186 shares. The stock had previously closed at $22.04.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on PCRX. Royal Bank of Canada reissued a “sector perform” rating and issued a $18.00 target price on shares of Pacira BioSciences in a research note on Tuesday, January 14th. HC Wainwright lifted their price target on shares of Pacira BioSciences from $57.00 to $70.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Needham & Company LLC raised their target price on Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Truist Financial upgraded Pacira BioSciences from a “sell” rating to a “hold” rating and lifted their target price for the company from $8.00 to $25.00 in a research report on Thursday, January 30th. Finally, Barclays increased their price target on Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a report on Friday, February 28th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $27.22.

Pacira BioSciences Trading Up 5.5 %

The company’s fifty day moving average is $23.78 and its two-hundred day moving average is $19.16. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. The stock has a market cap of $1.08 billion, a price-to-earnings ratio of -11.58 and a beta of 0.86.

Hedge Funds Weigh In On Pacira BioSciences

Large investors have recently bought and sold shares of the business. Sterling Capital Management LLC raised its position in shares of Pacira BioSciences by 779.4% during the 4th quarter. Sterling Capital Management LLC now owns 1,363 shares of the company’s stock worth $26,000 after acquiring an additional 1,208 shares in the last quarter. Ancora Advisors LLC acquired a new stake in Pacira BioSciences during the 4th quarter worth $26,000. Caitlin John LLC boosted its stake in Pacira BioSciences by 1,850.0% in the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock valued at $35,000 after acquiring an additional 1,776 shares in the last quarter. Nisa Investment Advisors LLC grew its holdings in shares of Pacira BioSciences by 495.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock worth $62,000 after purchasing an additional 2,749 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its position in shares of Pacira BioSciences by 16.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock worth $68,000 after purchasing an additional 513 shares in the last quarter. Hedge funds and other institutional investors own 99.73% of the company’s stock.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.